STOCKS TELEGRAPH

Tag: NRXP stock

  • Equity News Drives NRx Pharmaceuticals (NRXP) Stock Higher

    Equity News Drives NRx Pharmaceuticals (NRXP) Stock Higher

    Shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) have experienced a remarkable surge of 21.05%, reaching $3.45 as of the latest market check, following the announcement of an equity move. This notable increase comes after the company revealed its plan to raise capital through a registered direct offering of common stock.

    Senior Secured Convertible Notes and Equity Offering

    The pharmaceutical business has signed a legally binding contract to sell its common shares in a registered direct offering, with an anticipated gross profit of about $3.5 million. NRx Pharmaceuticals intends to issue senior secured convertible promissory notes in addition to the stock offering, which should generate an extra $5.4 million from the same institutional investors. The securities purchase agreement dated August 12, 2024, is in compliance with this issuance.

    Funding to Support Key Initiatives

    NRx intends to use the proceeds from both the stock offering and the notes issuance to support several critical initiatives, including the filing of New Drug Applications (NDAs) for its lead products, NRX-100 and NRX-101. These drugs are designed to address suicidal depression and potentially PTSD, both conditions that have long required new treatment options.

    Additionally, the funds will support the launch of HOPE Therapeutics, an initiative focused on delivering cutting-edge psychiatric care, and potentially fund the acquisition of additional pipeline assets.

    Path to Profitability

    The combined financing is expected to sustain the company’s operations through 2026, bolstered by anticipated product sales and non-dilutive funding. NRx Pharmaceuticals is confident that this financial strategy will enable the company to reach profitability. Furthermore, the funding could help close non-dilutive financing aimed at acquiring profitable interventional psychiatry clinics to expand HOPE Therapeutics’ reach.

    Impressive Market Performance

    NRXP stock has experienced a remarkable 90% rise over the past month, drawing attention from investors. Those seeking detailed insights on high-performing stocks in the Biotechnology industry are encouraged to explore our ST screener list for informed decision-making.

  • NRx Pharmaceuticals (NRXP) Stock Rises Amid Upcoming Investor Workshop

    NRx Pharmaceuticals (NRXP) Stock Rises Amid Upcoming Investor Workshop

    Shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) rose 12.71% to $3.37 in pre-event trading as the company’s subsidiary, HOPE Therapeutics, Inc., announced a pivotal investor workshop. This event targets Qualified Institutional Investors and aims to support the acquisition of interventional psychiatry clinics specializing in treatments for suicidal depression and PTSD.

    Strategic Acquisitions for Expanding Psychiatry Network

    HOPE Therapeutics has revealed non-binding Letters of Intent and preliminary financing agreements for the purchase of clinics that are anticipated to bring in more than $100 million annually by 2025. Facilities with proven patient bases and multimodal care services, such as ketamine therapy and transcranial magnetic stimulation (TMS), are the emphasis of the company’s acquisition strategy.

    David Feifel, MD, PhD, the appointed Chief Medical Innovation Officer, and Jonathan Javitt, MD, MPH, Chairman and Co-CEO of HOPE Therapeutics, will be in charge of the investor event. They will provide updates on tNRx Pharmaceuticals’ roadmap and answer questions regarding upcoming acquisitions. The workshop is scheduled for the week of January 6, 2025, with participation limited to institutional investors prepared to commit at least $5 million in secured acquisition funding.

    Kadima Neuropsychiatry Institute Acquisition Announced

    As part of its growth strategy, HOPE Therapeutics has confirmed plans to acquire the Kadima Neuropsychiatry Institute in La Jolla, California. This acquisition, outlined in a previously announced Letter of Intent, positions Kadima as the flagship clinic in HOPE’s international network of interventional psychiatry practices.

    Globally renowned for developing Ketamine Therapy for Central Nervous System (CNS) diseases, Kadima provides cutting-edge therapies for PTSD, anxiety, suicidal depression, and other CNS problems. These consist of TMS, Spravato (nasal esketamine), Ketamine Therapy, and complete pharmaceutical management. The research branch of Kadima is a leading investigative location in significant clinical trials and at the forefront of psychedelic therapeutic investigations.

    Dedication to Veteran and Military Care 

    Additionally, Kadima treats active-duty military people under Tricare and other defense-related programs and has contracts with the US Department of Veterans Affairs; in line with HOPE’s objective to improve mental health services by using cutting-edge, research-proven treatments.

    The goal of NRx Pharmaceuticals (NRXP) and HOPE Therapeutics’ strategic expansion is to strengthen their position as industry leaders in interventional psychiatry while promoting advancements in mental health care.

  • Further Growth Catalysts for NRx Pharmaceuticals (NRXP)

    The clinical stage, pharmaceutical company, NRx (NASDAQ: NRXP) Pharmaceuticals has been the talk of the town lately. It recently saw a significant 60% surge, which it has managed to sustain throughout the month of August. Some suggest that a further growth catalyst may very well take the stock to even greater heights.

    Impressive Rise for NRXP

    NRx Pharmaceuticals has been making the rounds across market chatter, with many investors discussing its stock prospects going forward. At the onset of August, the stock shot up from $0.51 to $0.82, in a 60% surge. What is most impressive about this jump is that NRXPP has maintained most of these gains all through August, still trading at these highs. What is most interesting about the jump is that there remains no identifiable catalyst that explains the jump. In fact, the company had been dealt a blow when the FDA refused to authorize its ZYESAMI drug for emergency use in Covid-19 treatment. However, the volume surge from 200,000 to over 25 million suggests NRXP gained meme-like popularity, in what seems to be a classic ‘pump and dump’ strategy.

    Further NRXP Growth Catalyst

    On Monday, a potential catalyst emerged, that many in the market have been discussing, and has pushed NRXP slightly up by 5%. The company had announced the reactivation of development in its psychiatry franchise. Within this class, there were several compounds in different research phases that had remained of low priority to management. This reorientation suggests a strategic shift, which could allow the company to gain access to the globally lucrative market of psychiatric medication.

    Conclusion

    NRXP achieved remarkable gains as the month began. No identifiable catalysts explain the rise, but the growth could have started off as a ‘pump and dump’ strategy, in which investors eventually realized the undervaluation cautions against selling. Many anticipate a further rise with the reactivation of psychiatry medication.

  • NRx Pharmaceuticals Inc. (NRXP) Bullish After Hours on its Upcoming COVID-19 Vaccine Presentation

    On January 07, NRx Pharmaceuticals Inc. (NRXP) announced its upcoming company updates presentation at the H.C. Wainwright BioConnect conference. The company will be discussing new details of its Covid-19 vaccine trial during the presentation. Consequently, the stock became bullish in the after-hours on the news.

    During regular trading, NRXP stock lost 7.34% at its closing price of $4.67 on Friday. Following the announcement, the stock gained 6.85% at $4.99 in the after-hours session.

    The clinical-stage small molecule pharmaceutical company, NRx Pharmaceuticals Inc. has a market capitalization of $274.64 million. Currently, the company has 58.81 million shares outstanding in the market.

    NRXP Recent Developments

    As per Friday’s latest announcement, the company will be presenting at the H.C. Wainwright BioConnect Virtual Conference, on January 10, 2022. The Chairman of NXRP’s Board and CEO, Prof. Jonathan Javitt, MD, MPH will be discussing the company’s business updates. Further, he will also provide new details on the company’s late-stage trials of BriLifeTM Covid-19 vaccine.

    NRXP is developing BriLifeTM vaccines against Covid-19. It is being developed under exclusive license from the Israel Ministry of Defense by the Institute for Biological Research. As new strains of the SARS-CoV-2 virus are emerging, the company is expanding its trials to include the new variants. Furthermore, the preliminary data showed the effectiveness of its BriLife vaccines against the Delta variant, last month. Moreover, the company has also advanced to now include reviewing data on BriLife vaccine’s effectiveness against the Omicron Variant.

    Hence, the company plans on presenting the preliminary data along with new developments in the vaccine’s clinical trials in the upcoming conference.

    In addition, the company also announced a change in the timings of the presentation. Previously, it was to be at 7 am EST on Monday, which has now been updated to 9 am EST on Monday.

    Q3 Financial Updates

    On November 16, the company announced its financial results for the third quarter of 2021, which ended on September 30, 2021.

    NRXP incurred a net loss of $20.8 million in the third quarter of 2021, against $5.2 million in Q3 of 2020. Resultantly, the net loss per basic and diluted share in the third quarter of 2021, was $0.40, against $0.15 in the year-ago period.

    Moreover, in the Q3 of 2021, the Research and Development expenses, and the General and Administrative expenses were $6.3 million and $13.8 million, respectively. This compares to respective $4.3 million and $3.8 million in Q3 of 2020.

  • NRx Pharmaceuticals, Inc. (NRXP) Stock Surges ZYESAMI Role in Pandemic Response

    NRx Pharmaceuticals, Inc. (NRXP) Stock Surges ZYESAMI Role in Pandemic Response

    NRx Pharmaceuticals, Inc. (NRXP) stock prices skyrocketed by 42.84% shortly after market trading commenced on July 19th 2021, bringing the price per share up to USD$12.17 early on in the trading day.

    ZYESAMI’s Role in Covid-19

    July 21st, 2021 saw the company announce data about ZYESAMI (aviptadil) at the Disease Control and Prevention Summit., in regard to the role of the treatment in preventing Cytokine Storm in Covid-19 patients. The presentation will showcase the statistically significant effect of ZYESAMI in mitigating the sharp rise in cytokines, which are closely linked to mortality in Covid-19 patients. This was consolidated by the completion of a recent Phase 2b/3 trial of ZYESAMI, wherein the change in cytokine level was a prespecified endpoint.

    Details of the Study

    Patients treated in the study showed a minimal increase in IL-6, as compared to patients treated with a placebo reported a statistically significant elevation in interleukin 6 cytokine levels. The patient set was diverse, with varying levels of the severity of Covid-19 infection and distribution among both tertiary care and community hospitals.

    Accelerated Development

    The findings have been submitted to the U.S. Food and Drug Administration as supplements to the Emergency Use Authorization application that has been submitted as is currently pending. The company is also submitting a biomarker letter of intent to the FDA as a part of its biomarker program, as pre the authorization of the 21st Century Cures Act.

    Scope of ZYESAMI

    With Covid-19 hospitalizations continuing to rise around the world, the placebo-controlled biomarker data signals the critical role that ZYESAMI has the potential to play in the prevention of the sudden elevation of cytokines that is linked to mortality. A biomarker-based regulatory path seems cleared on the basis of the link established between the clinical effect of ZYESAMI on survival and recovery in conjunction with measurable biologic chance in cytokine levels. The effects of a cytokine storm are lethal and are associated with mortality resulting from a variety of fatal conditions, including, but not limited to, Acute Respiratory Distress Syndrome, a common cause of death in sepsis, and amniotic fluid embolus.

    Future Outlook for NRXP

    Armed with a highly promising advancement in the fight against the continuing global coronavirus pandemic, NRXP is poised to capitalize on the prospective market space that has become accessible to it. With such spearheaded market penetration, current and potential investors are hopeful that management will be able to leverage their resources to facilitate effective distribution of the offering in a timely manner to ensure maximum profitability.